Adaptive Biotechnologies (NASDAQ: ADPT) reported Q1 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $41.87 million versus the consensus estimate of $38.79 million.

2024 Updated Financial Guidance

Adaptive Biotechnologies expects full year revenue for the MRD business to be between $135 million and $140 million, updated from the previous range between $130 million and $140 million. No revenue guidance is provided for the Immune Medicine business.

We expect full year total company operating expenses, including cost of revenue, to be between $350 million and $360 million, updated from the previous range between $360 million and $370 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.